Nosocomial bacterial infections in intensive care units. I: Organisms and mechanisms of antibiotic resistance

Anaesthesia

Volumn 60, Issue 9, 2005, Pages 887-902

  Lim, Soo Ming ^a   Webb, S A R ^b,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFALOTIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLAVULANIC ACID; DICLOXACILLIN; FLUCLOXACILLIN; FUSIDIC ACID; IMIPENEM; LINEZOLID; MEROPENEM; METICILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TAZOBACTAM; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INACTIVATION; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENTEROBACTER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOMENOLOGY; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS;

EID: 23944508575     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04220.x     Document Type: Review

References (129)

1. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120: 2059-93.
2. Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999; 115: 34S-41S.
3. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Medicine 2002; 28: 108-21.
4. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association 1995; 274: 639-44.
5. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. American Journal of Respiratory and Critical Care Medicine 1999; 159: 1249-56.
6. Blot SI, Vandewoude KH, Colardyn FA. Evaluation of outcome in critically ill patients with nosocomial enterobacter bacteremia: results of a matched cohort study. Chest 2003; 123: 1208-13.
7. Blot S, Vandewoude K, Hoste E, Colardyn F. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. Journal of Hospital Infection 2003; 53: 18-24.
8. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Medicine 2003; 29: 471-5.
9. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Archives of Surgery 2001; 136: 229-34.
10. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. American Journal of Respiratory and Critical Care Medicine 1999; 160: 976-81.
11. Haley RW, Culver DH, White JW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. American Journal of Epidemiology 1985; 121: 182-205.
12. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Critical Care Medicine 2001; 29: 2303-9.
13. Renaud B, Brun-Buisson C. ICU-Bacteremia Study Group. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. American Journal of Respiratory and Critical Care Medicine 2001; 163: 1584-90.
14. Reuter S, Sigge A, Wiedeck H, Trautmann M. Analysis of transmission pathways of Pseudomonas aeruginosa between patients and tap water outlets. Critical Care Medicine 2002; 30: 2222-8.
15. Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Seminars in Respiratory Infections 2000; 15: 287-98.
16. Govan JRW. Pseudomonads and non-fermenters. In: Greenwood D, Slack R, Peutherer J, eds. Medical Microbiology. A Guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Diagnosis and Control. Edinburgh: Churchill Livingstone, 1997: 284-9.
17. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clinical Microbiology Reviews 1996; 9: 148-65.
18. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgraduate Medical Journal 2002; 78: 385-92.
19. Pittet D, Dharan S, Touveneau S, Sauvan V, Perneger TV. Bacterial contamination of the hands of hospital staff during routine patient care. Archives of Internal Medicine 1999; 159: 821-6.
20. Howe RA, Brown NM, Spencer RC. The new threats of Gram positive pathogens: re-emergence of things past. Journal of Clinical Pathology 1996; 49: 444-9.
21. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews 2001; 14: 933-51.
22. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Critical Care Medicine 2001; 29: N75-N81.
23. Nordmann P. Trends in beta-lactam resistance among Enterobacteriaceae. Clinical Infectious Diseases 1998; 27: S100-S106.
24. Sanders WE Jr, Sanders CC. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clinical Microbiology Reviews 1997; 10: 220-41.
25. Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. Journal of Antimicrobial Chemotherapy 2001; 48: S59-S64.
26. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 1994; 38: 2231-7.
27. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infectious Diseases 2001; 1: 147-55.
28. Jacoby GA. Antimicrobial action and resistance. In: Root RK, Waldvogel F, Corey L, Stamm WE, eds. Clinical Infectious Disease: A Practical Approach. New York: Oxford University Press, 1999: 209-15.
29. Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clinical Microbiology Reviews 1997; 10: 781-91.
30. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clinical Microbiology Reviews 2000; 13: 686-707.
31. Henwood CJ, Livermore DM, James D, Warner M. Pseudomonas Study Group. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. Journal of Antimicrobial Chemotherapy 2001; 47: 789-99.
32. Elliott TS, Lambert PA. Antibacterial resistance in the intensive care unit: mechanisms and management. British Medical Bulletin 1999; 55: 259-76.
33. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrobial Agents and Chemotherapy 2000; 44: 2233-41.
34. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrobial Agents and Chemotherapy 2000; 44: 2595-9.
35. Livermore DM. of Pseudomonas, porins, pumps and carbapenems. Journal of Antimicrobial Chemotherapy 2001; 47: 247-50.
36. Lowy FD. Staphylococcus aureus infections. New England Journal of Medicine 1998; 339: 520-32.
37. Hiramatsu K. Reduced susceptibility of Staphylococcus aureus to Vancomycin - Japan 1996. MMWR Morbidity and Mortality Weekly Report 1997; 46: 624-6.
38. Stefani S, Varaldo PE. Epidemiology of methicillin-resistant staphylococci in Europe. Clinical Microbiology and Infection 2003; 9: 1179-86.
39. National Nosocomial Infections Surveillance system. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992 to June 2001, issued August 2001. American Journal of Infection Control 2001; 29: 404-21.
40. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 1997; 40: 135-6.
41. McGowan JE Jr. Increasing threat of Gram-positive bacterial infections in the intensive care unit setting. Critical Care Medicine 2001; 29: N69-N74.
42. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clinical Infectious Diseases 2001; 32: 108-15.
43. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States 1997-2001. Clinical Infectious Diseases 2003; 36: 429-39.
44. Hiramatsu K, Okuma K, Ma XX, Yamamoto M, Hori S, Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Current Opinion in Infectious Diseases 2002; 15: 407-13.
45. Martin R, Wilcox KR. Staphylococcus aureus with reduced susceptibility to vancomycin - United States 1997. MMWR Morbidity and Mortality Weekly Report 1997; 46: 765-6.
46. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. New England Journal of Medicine 1999; 340: 493-501.
47. Sievert DM, Boulton ML, Stoltman G, et al. Staphylococcus aureus resistant to vancomycin - United States 2002. MMWR Morbidity and Mortality Weekly Report 2002; 51: 565-7.
48. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R. Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Critical Care Medicine 1999; 27: 798-801.
49. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. New England Journal of Medicine 2002; 346: 1871-7.
50. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clinical Microbiology Reviews 1997; 10: 505-20.
51. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. American Journal of Medicine 1996; 100: 509-16.
52. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Annals of Thoracic Surgery 2001; 71: 1572-9.
53. Reese RE, Betts RF, Gumustop B. Penicillinase-resistant penicillins. In: Handbook of Antibiotics. Philadelphia: Lippincott, Williams & Wilkins, 2000: 339-42.
54. Chastre J, Fagon JY. Ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2002; 165: 867-903.
55. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clinical Infectious Diseases 1999; 29: 239-44.
56. Reese RE, Betts RF, Gumustop B. Broad-spectrum penicillins and beta-lactam/beta-lactamase combinations. In: Handbook of Antibiotics. Philadelphia: Lippincott, Williams & Wilkins, 2000:343-64.
57. Reese RE, Betts RF, Gumustop B. Unique beta-lactam antibiotics. Monobactams and carbapenems (Aztreonam, Imipenem, and Meropenem). In: Handbook of Antibiotics. Philadelphia: Lippincott, Williams & Wilkins, 2000: 401-14.
58. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy 1997; 39: S1-S6.
59. Reese RE, Betts RF, Gumustop B. Vancomycin, linezolid, and Quinupristin/Dalfopristin. In: Handbook of Antibiotics. Philadelphia: Lippincott, Williams & Wilkins, 2000:503-20.
60. Rubinstein E, Bompart F. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential. Journal of Antimicrobial Chemotherapy 1997; 39: S139-S43.
61. Pechere JC. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. Journal of Antimicrobial Chemotherapy 1999; 44: S11-S8.
62. Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy 1999; 44: S31-S6.
63. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. American Journal of Respiratory and Critical Care Medicine 2000; 161: 753-62.
64. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical Infectious Diseases 2001; 32: 402-12.
65. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 2002; 34: 1481-90.
66. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
67. Whitby M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 1999; 12: S67-S71.
68. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clinical Microbiology Reviews 2002; 15: 430-8.
69. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
70. Huebner J. Goldmann DA. Coagulase-negative staphylococci: role as pathogens. Annual Review of Medicine 1999; 50: 223-36.
71. von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infectious Diseases 2002; 2: 677-85.
72. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. European Journal of Clinical Microbiology and Infectious Diseases 1996; 15: 281-5.
73. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-82.
74. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Annals of International Medicine 2003; 138: 135-42.
75. Aldridge KE, Schiro DD, Varner LM. In vitro anti-staphylococcal activity and testing of RP 59500, a new streptogramin, by two methods. Antimicrobial Agents and Chemotherapy 1992; 36: 854-5.
76. Woodford N, Johnson AP, Morrison D, Speller DC. Current perspectives on glycopeptide resistance. Clinical Microbiology Reviews 1995; 8: 585-615.
77. Murray BE. Vancomycin-resistant enterococcal infections. New England Journal of Medicine 2000; 342: 710-21.
78. Moellering RC Jr. Vancomycin-resistant enterococci. Clinical Infectious Diseases 1998; 26: 1196-9.
79. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A, European VRE Study Group. Prevalence of vancomycin-resistant enterococci in Europe. European Journal of Clinical Microbiology and Infectious Diseases 2000; 19: 816-22.
80. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the. SENTRY Antimicrobial Surveillance Program 1997-99. Clinical Infectious Diseases 2001; 32: S133-S145.
81. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infectious Diseases 2001; 1: 314-25.
82. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348: 1615-9.
83. Hayden MK. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. Clinical Infectious Diseases 2000; 31: 1058-65.
84. Donskey CJ, Chowdhry TK, Hecker MT et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. New England Journal of Medicine 2000; 343: 1925-32.
85. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of 'colonization pressure' in the spread of vancomycin-resistant enterococci: an important infection control variable. Archives of International Medicine 1998; 158: 1127-32.
86. French GL. Enterococci and vancomycin resistance. Clinical Infectious Diseases 1998; 27: S75-S83.
87. Johnson AP, Warner M, Woodford N, Speller DC, Livermore DM. Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory. British Medical Journal 1998; 317: 629-30.
88. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. Journal of Antimicrobial Chemotherapy 2002; 49: 437-44.
89. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. New England Journal of Medicine 1996; 335: 1445-53.
90. Murray BE. Vancomycin-resistant enterococci. American Journal of Medicine 1997; 102: 284-93.
91. Landman D, Quale JM. Management of infections due to resistant enterococci: a review of therapeutic options. Journal of Antimicrobial Chemotherapy 1997; 40: 161-70.
92. Chow JW. Aminoglycoside resistance in enterococci. Clinical Infectious Diseases 2000; 31: 586-9.
93. Johnson AP, Warner M, Hallas G, Livermore DM. Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999. Journal of Antimicrobial Chemotherapy 2000; 46: 125-8.
94. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/ dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clinical Infectious Diseases 1998; 27: 1554-6.
95. Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1999; 43: 2776-9.
96. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994; 344: 1025-6.
97. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. Journal of Antimicrobial Chemotherapy 1997; 39: S145-51.
98. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. Journal of Antimicrobial Chemotherapy 1999; 44: 251-61.
99. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrobial Agents and Chemotherapy 1996; 40: 1745-7.
100. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clinical Infectious Diseases 1999; 28: 689-90.
101. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Critical Care Medicine 2001; 29: 2383-5.
102. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clinical Infectious Diseases 2001; 33: 477-82.
103. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
104. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagnostic Microbiology and Infectious Disease 1998; 30: 109-12.
105. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clinical Infectious Diseases 1998; 27: 1259-65.
106. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical Microbiology Reviews 1998; 11: 589-603.
107. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clinical Microbiology and Infection 2000; 6: 460-3.
108. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. Journal of Antimicrobial Chemotherapy 2000; 45: 183-9.
109. Drusano GL. Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clinical Infectious Diseases 1998; 27: S111-S116.
110. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clinical Infectious Diseases 2000; 30: 473-8.
111. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrobial Agents and Chemotherapy 1997; 41: 563-9.
112. Penn RL, Betts RF. Lower respiratory tract infections (including tuberculosis). In: Betts RF, Chapman SW, Penn RL, eds. A Practical Approach to Infectious Diseases. Philadephia: Lippincott, Williams & Wilkins, 2003: 295-371.
113. Wilson R, Dowling RB. Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax 1998; 53: 213-9.
114. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global. SENTRY Antimicrobial Surveillance Program. 1997-1999. Clinical Infectious Diseases 2001; 32: S146-S155.
115. Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ, Pfaller MA, Tenover PC, Yolken RH, eds. Manual of Clinical Microbiology. Washington DC: American Society for Microbiology Press, 1999: 517-25.
116. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Pseudomonas and related organisms. In: Brown M, ed. Medical Microbiology. St. Louis: Mosby-Year Book, 1998: 258-64.
117. Fagon JY, Chastre J, Domart Y, et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. American Review of Respiratory Disease 1989; 139: 877-84.
118. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990 to May 1999, issued June 1999. American Journal of Infection Contrology 1999; 27: 520-32.
119. Bertrand X, Thouverez M, Talon D, et al. Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units. Intensive Care Medicine 2001; 27: 1263-8.
120. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 1999; 43: 1379-82.
121. Fluit AC, Verhoef J, Schmitz FJ. Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. European SENTRY Participants. European Journal of Clinical Microbiology and Infectious Diseases 2000; 19: 370-4.
122. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. Journal of Antimicrobial Chemotherapy 2002; 49: 229-33.
123. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrobial Agents and Chemotherapy 1998; 42: 2966-72.
124. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. American Journal of Respiratory and Critical Care Medicine 1998; 157: 531-9.
125. Quinn JP. Clinical problems posed by multiresistant non-fermenting gram-negative pathogens. Clinical Infectious Diseases 1998; 27: S117-S24.
126. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clinical Microbiology Reviews 1995; 8: 557-84.
127. Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clinical Microbiology and Infection 2002; 8: 144-53.
128. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii. epidemiology, clinical features and treatment. Clinical Microbiology and Infection 2002; 8: 687-93.
129. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clinical Microbiology Reviews 1998; 11: 57-80.